Research Tools
Dose-Response Study Planner
Design multi-arm dose-response studies: log-spaced dose groups, statistically powered group sizes from published inter-animal variability data, expected effect sizes, and total compound requirements.
1. Select Compound
2. Study Parameters
3. Study Design Output
Power calculation: n = 5/group (80% power, α = 0.05, CV = 22%)
Vial estimate: ≈ 1 × 5 mg vials (assumes 5 mg/vial standard catalog size)
| Group | Dose | Absolute/Inj (mg) | n/Group | Total Compound (mg) | Expected Effect |
|---|---|---|---|---|---|
| Vehicle | 0 (vehicle) | — | 5 | — | Baseline ref. |
| Dose 1 | 0.50 mcg/kg | 12.50 ng | 5 | 875.0 ng | ~25% |
| Dose 2 | 2.92 mcg/kg | 73.00 ng | 5 | 5.11 µg | ~35% |
| Dose 3 | 17.1 mcg/kg | 427.50 ng | 5 | 29.93 µg | ~45% |
| Dose 4 | 100 mcg/kg | 2.50 µg | 5 | 175.00 µg | ~55% |
4. Dose-Response Curve (Estimated)
Log-linear interpolation from published literature. Not a fitted curve — use actual experimental data for final curve fitting.
5. Group Size vs. Effect Size Reference
Required n per group (80% power, α = 0.05, two-sample t-test) for BPC-157 with CV = 22%. Based on published inter-animal variability for this compound's endpoint: Tendon tensile strength / wound area.
| Expected Effect Size | Required n / Group | 4-group study (excl. vehicle) | Feasibility |
|---|---|---|---|
| 10% | 76 | 304 animals | ✗ Large study |
| 20% | 19 | 76 animals | ⚠ Moderate |
| 30% | 9 | 36 animals | ✓ Feasible |
| 40% ← BPC-157 | 5 | 20 animals | ✓ Feasible |
| 50% | 5 | 20 animals | ✓ Feasible |
| 60% | 5 | 20 animals | ✓ Feasible |
| 75% | 5 | 20 animals | ✓ Feasible |
6. Research Design Considerations
Log-Scale Dose Spacing
Log-spaced doses (e.g., 1, 3, 10, 30 mcg/kg) are standard for dose-response studies because biological systems typically exhibit log-linear relationships between dose and effect. Equal linear spacing concentrates arms in a narrow effective range.
Vehicle Control Design
Vehicle controls receive the same reconstitution buffer (BAC water, saline, PBS) at the same volume and route as treatment groups. This isolates compound-specific effects from injection stress, solvent effects, and handling variability.
Statistical Power & CV%
Group size calculations use compound-specific CV% from published preclinical data (BPC-157: 22% CV). Higher biological variability requires larger groups. Use pilot data to refine CV estimates before committing to full study cohorts.
Endpoint Timing
For BPC-157, the recommended endpoint is: Tendon tensile strength / wound area. Assess at the correct time post-treatment (14 days standard) — premature assessment underestimates maximum effect.
Pair-Fed Controls
For metabolic endpoints (body weight, fat mass, glucose), include a pair-fed control group matching caloric intake of the highest-dose group. This distinguishes anorexigenic effects from direct metabolic mechanism.
Blinding & Randomization
Randomize animals to groups by weight-stratified randomization at study start. Blind investigators to treatment group for behavioral, histological, and ELISA endpoints. Document randomization scheme in IACUC protocol.
Compound Reference: Dose-Response Data
Published preclinical dose ranges, endpoints, and inter-animal variability (CV%) for all catalog compounds.
| Compound | Category | Published Range | Typical Dose | Endpoint | CV% | Study Days |
|---|---|---|---|---|---|---|
| BPC-157 | Recovery & Healing | 0.5–100 mcg/kg | 10 mcg/kg | Tendon tensile strength / wound area | 22% | 14 |
| TB-500 (Thymosin Beta-4) | Recovery & Healing | 0.1–6 mg/kg | 2 mg/kg | Tendon repair score / wound closure % | 25% | 21 |
| GHK-Cu | Recovery & Healing | 0.1–10 mg/kg | 1 mg/kg | Wound contraction area / collagen content | 28% | 28 |
| Wolverine Blend (BPC-157+TB-500+GHK-Cu) | Recovery & Healing | 2–20 mcg/kg | 10 mcg/kg | Composite repair score | 27% | 21 |
| Ipamorelin | GH Axis | 10–500 mcg/kg | 100 mcg/kg | Peak GH (ng/mL) / IGF-1 (ng/mL) | 18% | 84 |
| CJC-1295 No DAC (Mod GRF 1-29) | GH Axis | 10–300 mcg/kg | 100 mcg/kg | Peak GH (ng/mL) / IGF-1 (ng/mL) | 20% | 56 |
| Sermorelin | GH Axis | 5–200 mcg/kg | 30 mcg/kg | IGF-1 (% elevation from baseline) | 22% | 56 |
| MK-677 (Ibutamoren) | GH Axis | 1–50 mg/kg | 10 mg/kg | IGF-1 (ng/mL) / lean mass (g) | 15% | 56 |
| Tesamorelin | GH Axis | 50–500 mcg/kg | 200 mcg/kg | VAT area (cm²) / IGF-1 (ng/mL) | 22% | 56 |
| Hexarelin | GH Axis | 20–320 mcg/kg | 80 mcg/kg | Peak GH (ng/mL) / infarct size (%) | 20% | 28 |
| Semaglutide | Metabolic | 0.01–3 mg/kg | 0.1 mg/kg | Body weight (%) / fat mass (DEXA) | 12% | 56 |
| Tirzepatide | Metabolic | 0.01–10 mg/kg | 0.3 mg/kg | Body weight (%) / fat mass / HbA1c | 12% | 56 |
| Retatrutide | Metabolic | 0.01–10 mg/kg | 0.3 mg/kg | Body weight (%) / hepatic fat / lean mass | 13% | 56 |
| MOTS-c | Metabolic | 0.1–20 mg/kg | 5 mg/kg | Fasting glucose / insulin sensitivity (GTT) | 24% | 42 |
| NAD+ | Longevity | 50–1000 mg/kg | 500 mg/kg | NAD+/NADH tissue ratio / SIRT1 activity | 30% | 28 |
| Epitalon | Longevity | 20–200 mcg/kg | 40 mcg/kg | Telomerase activity (TRAP) / IGF-1 / cancer incidence | 35% | 365 |
| SS-31 (Elamipretide) | Longevity | 0.1–10 mg/kg | 3 mg/kg | Mitochondrial CRC / Complex I activity / LVEF | 22% | 28 |
| Semax | Nootropics | 25–500 mcg/kg | 100 mcg/kg | BDNF (pg/mL) / hippocampal neurogenesis / MWM latency | 28% | 14 |
| Selank | Nootropics | 100–3000 mcg/kg | 300 mcg/kg | Anxiety index (EPM/OFT) / BDNF / IL-6 (pg/mL) | 25% | 14 |
| DSIP (Delta Sleep-Inducing Peptide) | Nootropics | 20–500 mcg/kg | 100 mcg/kg | EEG delta wave % / NREM duration (min) | 32% | 7 |
| KPV (α-MSH C-terminal tripeptide) | Immunology | 0.01–5 mg/kg | 0.1 mg/kg | MPO activity / colon crypt preservation / TNF-α (pg/mL) | 24% | 14 |
| PT-141 (Bremelanotide) | Immunology | 0.1–10 mg/kg | 1 mg/kg | Lordosis quotient / mount latency (sec) | 30% | 7 |
| AOD-9604 | Metabolic | 50–5000 mcg/kg | 500 mcg/kg | Body fat % (DEXA) / lipolysis (glycerol release) | 20% | 42 |
| Melanotan II | Recovery & Healing | 0.05–2 mg/kg | 0.3 mg/kg | Skin OD (melanin) / erythema index / sexual behavior | 28% | 14 |